Search Results

Research and Innovation

At MSD Animal Health, our scientists and experts are constantly searching for ways to advance the state of veterinary medicine and animal health.

Homepage

MSD Animal Health – Information on veterinary products, technologies and veterinary services that truly advance animal healthcare.

News Releases

Mexico’s SADER Approves MSD Animal Health’s EXZOLT® 5% Pour-On (Fluralaner 50 mg/mL) for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (Myiasis)

MSD Animal Health, a division of MSD & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the Mexico’s SADER Approval of EXZOLT® 5% Pour-On (Fluralaner 50 mg/mL) for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (Myiasis)

Featured Stories

Enhancing Multivalent Inactivated Vaccines for Long-Living Birds

Poultry is a cornerstone of global food security. It provides affordable, high-quality protein in the form of both meat and eggs, feeding billions of people worldwide.

News Releases

New Data from MSD Animal Health Demonstrates that Intranasal Vaccination Against Bovine Coronavirus with BOVILIS® NASALGEN®-C (Lyophilisate and Solvent for Suspension for Cattle) Significantly Improves Production in Veal Calves

MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the presentation of new data in support of intranasal vaccination for the prevention of bovine coronavirus (BCoV) with BOVILIS® NASALGEN®-C. These data were presented at the Vlaamse Buiatriecongres 2025 (the Flemish Buiatrics Congress), October 23-24.

News Releases

MSD Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress

Additional educational symposia offer the latest information on vector-borne diseases, infectious diseases and treatment and prevention protocols Rahway, NJ, September 26, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple

News Releases

MSD Animal Health Strengthens Its Dedication to Rabies Elimination with 7 Millionth Vaccine Donation Through the Afya Program

RAHWAY, N.J., Sept. 26, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated more than seven million NOBIVAC® rabies vaccines through the Company’s Afya Program, since it was founded.

News Releases

MSD Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress

MSD Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs

News Releases

MSD Animal Health Launches NUMELVI® (atinvicitinib) Tablets for Dogs – A Veterinary Innovation in Fast, Effective and Safe Targeted Itch Relief

MSD Animal Health today announced that the European Commission has approved NUMELVI™ (atinvicitinib) Tablets for Dogs.

News Releases

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New MSD Animal Health Global Survey Finds

Data show pet owners face difficulties with consistent compliance, while veterinarians worry about inconsistent or incorrect medication administration In the U.S. Two-thirds of veterinarians note that most pet owners do not follow year-round treatment plan, despite evidence that fleas and tick are present during all seasons RAHWAY, N.J., August 19, 2025

News Releases

MSD Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress

Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations RAHWAY, N.J., August 18, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will

News Releases

European Commission Approves NUMELVI™ (atinvicitinib) Tablets for Dogs

NUMELVI from MSd Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs